The document also adds that the proposed changes by the WHO could give people the wrong idea, leading them to think that the current Schedule IV stance impedes research and that the international framework isn’t compatible with research. What they’re basically saying is that even if the United States acknowledges the benefits of reclassifying cannabis, the government is worried about how it would turn out.
Trulieve becomes the first U.S. cannabis company to trade on the NYSE on June 10.…
From robot canopy scanners to algorithmic breeders to AI-powered dispensary counters, artificial intelligence is remaking…
The latest version of this story comes from Virginia Commonwealth University, where researcher Emanuele Alves…
But there's more to this image than nostalgia and comedy. What you're looking at in…
The league pulled marijuana off its banned list in the new players’ agreement. In the…
In New South Wales, Australia, patients can legally use medical cannabis with a prescription. So…